CardioExchange Archive

April 21st, 2014

The CoreValve Trial: What Do You Say to Your Patients?

Harlan M. Krumholz, MD, SM

Harlan Krumholz presents a scenario based on the CoreValve trial and asks, “What do you say to your patient?”

---

March 31st, 2014

Are We Equipped to Make a CHOICE Between TAVR Devices?

E Murat Tuzcu, MD

E. Murat Tuzcu offers his perspective on the CHOICE trial comparing the CoreValve and Edwards Sapien XT devices for transcatheter aortic valve replacement.

---

March 30th, 2014

Taking Patient-Centeredness to the Next Level at ACC.14

Kumar Dharmarajan, MD MBA

A fellow discusses an interesting lecture approach at ACC.14.

---

March 29th, 2014

TAVR: Are You Impressed Now?

Ajay J Kirtane, MD, SM

Interventionalist Ajay Kirtane offers his perspective on the new randomized trial comparing transcatheter (CoreValve) with surgical aortic valve replacement.

---

February 21st, 2014

Unpacking a Systematic Review of TAVR Research

Philip Green, MD and Kumar Dharmarajan, MD MBA

Philip Green and Kumar Dharmarajan explore how best to identify which patients benefit most from transcatheter aortic valve replacement.

---

July 15th, 2013

The Conundrum of Low-Gradient Severe Aortic Stenosis with Preserved LVEF

Thomas Marwick and John Ryan, MD

Thomas Marwick discusses his research group’s study of how patients who have severe aortic stenosis with low gradient and a preserved LV ejection fraction fare after aortic valve replacement.

---

February 11th, 2013

Selections from Richard Lehman’s Literature Review: February 11th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the effect of ramipril on walking times and quality of life among those with PAD and intermittent claudication, genetic associations with valvular calcification and aortic stenosis, and more.

---

November 4th, 2012

Management of Aortic Stenosis: Up Close and in Person

Megan Coylewright, MD MPH

An AHA.12 session on management of aortic stenosis includes an impressive line-up of experts and underscores the value of attending the meeting.

---

August 6th, 2012

TAVR and the Price of Innovation

Daniel Mark, Richard A. Lange, MD, MBA and L. David Hillis, MD

In an article published in Circulation, Daniel Mark and Robert Mentz of the Duke Clinical Research Institute and University Medical Center examine the economic and policy implications of the recent validation of transcatheter aortic valve replacement (TAVR) in the PARTNER trials. CardioExchange is fortunate and pleased to present Dr. Mark’s responses to questions about his […]

---

June 14th, 2012

FDA Advisory Panel Recommends Expanded Indication for Sapien Transcatheter Heart Valve

Larry Husten, PHD

The FDA’s Circulatory System Devices Panel voted overwhelmingly on Wednesday to recommend an expanded indication for the Edwards Sapien Transcatheter Heart Valve in patients with symptomatic severe aortic stenosis who have high operative risk. The device is currently approved for use only in patients who are not surgical candidates. The committee voted 10-2 that the Sapien device was […]

---